Further exploratory analysis using gene expression profiles (Fig. 5e) of SCLC patients indicated that KMT2D mutations affect various immune cell populations within the tumor microenvironment, including CD8+ T cells, Th1 cells, and M2 macrophages. The gene discussed is KMT2D; the disease is neoplasm.